TYKERB
Total Payments
$9.9M
Transactions
165
Doctors
8
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $1,500 | 1 | 0 |
| 2022 | $496,931 | 7 | 0 |
| 2021 | $497,009 | 16 | 0 |
| 2020 | $452,694 | 15 | 0 |
| 2019 | $1.6M | 31 | 0 |
| 2018 | $2.1M | 40 | 0 |
| 2017 | $4.8M | 55 | 8 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9.9M | 157 | 99.8% |
| Consulting Fee | $15,294 | 5 | 0.2% |
| Food and Beverage | $44.91 | 3 | 0.0% |
Payments by Type
Research
$9.9M
157 transactions
General
$15,339
8 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PHASE II TRIAL OF PULSE DOSING OF LAPATINIB IN COMBINATION WITH TEMOZOLOMIDE AND REGIONAL RADIATION THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME | Novartis Pharmaceuticals Corporation | $3.0M | 0 |
| A PHASE II RANDOMIZED DB PLACEBO CONTROLLED STUDYOF LAPATINIB WITH CHEMORADITION FOR NON HPV LOCALLY ADVANCED HEAD AND NECK CANCER | Novartis Pharmaceuticals Corporation | $859,814 | 0 |
| A PHASE II OPEN LABEL STUDY OF THE CLINICAL ACTIVITY SAFETY AND TOLERABILITY OF LAPATANIB IN COMBINATION WITH BEVACIZUMAB IN SUBJECTS WITH ADVANCED OR METASTATIC ERBB2 OVEREXPRESSING BREAST CANCER | Novartis Pharmaceuticals Corporation | $830,789 | 0 |
| PHASE I STUDY OF INTERMITTENT HIGH DOSE LAPATINIB IN TANDEM WITH CAPECITABINE FOR HER2 OVEREXPRESSED AND OR AMPLIFIED METASTATIC BREAST CANCER WITH CENTRAL NERVOUS SYSTEM CNS METASTASES | Novartis Pharmaceuticals Corporation | $800,419 | 0 |
| PHASE 2 LAPATINIB IN COMBINATION WITH TRASTUZUMAB IN PATIENTS WITH HER2 POSITIVE METASTATIC BREAST CANCER | Novartis Pharmaceuticals Corporation | $636,970 | 0 |
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED MULTICENTER PHASE III STUDY COMPARING THE ACTIVITY OF PACLITAXEL PLUS TRASTUZUMAB PLUS LAPATINIB TO PACLITAXEL PLUS TRASTUZUMAB PLUS PLACEBO IN WOMEN WITH ERBB2 OVEREXPRESSING METASTATIC BREAST CANCER | Novartis Pharmaceuticals Corporation | $600,671 | 0 |
| A PHASE I DOSE ESCALATION STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF LAPATINIB IN COMBINATION WITH CARBOPLATIN PACLITAXEL WITH AND WITHOUT TRASTUZUMAB IN SUBJECTS WITH METASTATIC BREAST CANCER | Novartis Pharmaceuticals Corporation | $497,882 | 0 |
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED MULTICENTER PHASE III STUDY COMPARING GW572016 AND LETROZOLE VERSUS LETROZOLE IN SUBJECTS WITH ESTROGEN AND OR PROGESTERONE RECEPTOR POSITIVE ADVANCED OR METASTATIC BREAST CANCER | Novartis Pharmaceuticals Corporation | $417,790 | 0 |
| RANDOMIZED OPEN LABEL PHASE II TRIAL OF NEOADJUVANT TRASTUZUMAB ENTANSINE TE IN COMBINATION WITH LAPATINIB FOLLOW BY ABRAXANE COMPARED WITH TRASTUZUMAB PLUS LAPATINIB FOLLOW BY PACLITAXEL IN HER 2 NEU OVER EXPRESSED BREAST CANCER PATIENTS | Novartis Pharmaceuticals Corporation | $286,682 | 0 |
| CLAP016B2301 | Novartis Pharma AG | $207,921 | 0 |
| PHASE II SINGLE ARM TRIAL EVALUATING THE COMBINATION OF LAPATINIB EVEROLIMUS AND CAPECITABINE OF THE TREATED OF PTS WITH HER2 POSITIVE METASTATIC BREAST CANCER WITH CNS PROGRESSION AFTER HER2 TARGETED THERAPY | Novartis Pharmaceuticals Corporation | $159,900 | 0 |
| PHASE II TRIAL OF METRONOMIC CAPECITABINE AND CYCLOPHOSPHAMIDE WITH LAPATINIB AND TRASTUZUMAB IN PATIENTS WITH HER2 POSITIVE METASTATIC BREAST CANCER WHO HAVE PROGRESSED ON A PREVIOUS TRASTUZUMABBASED REGIMEN | Novartis Pharmaceuticals Corporation | $141,632 | 0 |
| TREATMENT OF RECURRENT PITUITARY TUMORS WITH LAPATINB | Novartis Pharmaceuticals Corporation | $139,877 | 0 |
| MULTIMODALITY RISK ADAPTED THERAPY INCLUDING CARBOPLATIN PACLITAXEL LAPATINIB AS INDUCTION FOR SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AMENABLE TO TRANSORAL SURGICAL APPROACHES | Novartis Pharmaceuticals Corporation | $127,632 | 0 |
| PHASE II SINGLE-ARM TRIAL EVALUATING THE COMBINATION OF LAPATINIB, EVE | NOVARTIS PHARMACEUTICALS CORPORATION | $113,692 | 0 |
| ALTTO A RANDOMIZED MULTICENTRE OPEN LABEL PHASE III STUDY OF ADJUVANT LAPATINIB TRASTUZUMAB THEIR SEQUENCE AND THEIR COMBINATION IN PATIENTS WITH HER2 AND OR ERBB2 POSITIVE PRIMARY BREAST CANCER | Novartis Pharmaceuticals Corporation | $111,631 | 0 |
| A PHASE III TRIAL TO COMPARE THE SAFETY AND EFFICACY OF LAPATINIB PLUS TRASTUZUMAB PLUS AN AROMATASE INHIBITOR AI VERSUS TRASTUZUMAB PLUS AN AI VERSUS LAPATINIB PLUS AN AI AS FIRST OR SECOND LINE THERAPY IN POSTMENOPAUSAL SUBJECTS WITH HORMONE RECEPTOR POSITIVE HER2 POSITIVE METASTATIC BREAST CANCER MBC WHO HAVE RECEIVED PRIOR TRASTUZUMAB AND ENDOCRINE THERAPIES | Novartis Pharmaceuticals Corporation | $92,428 | 0 |
| TOLERABILITY OF THE COMBINATION OF LAPATINIB AND TRASTUZUMAB IN ADULTS AGED 60 OR OLDER WITH HER2 POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Novartis Pharmaceuticals Corporation | $88,490 | 0 |
| A PHASE II STUDY OF DOSE DENSE PACLLITAXEL WITH TRASTUZUMAB AND LAPATINIB IN HER2 AMPLIFIED BREAST CANCER | Novartis Pharmaceuticals Corporation | $77,824 | 0 |
| A NEOADJUVANT STUDY OF EXTENDED LAPATINIB, TRASTUZUMAB, WITH OR WITHOU | Novartis Pharmaceuticals Corporation | $69,500 | 0 |
Top Doctors Receiving Payments for TYKERB
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Los Angeles, CA | $9.9M | 157 |
| , M.D | Internal Medicine | Palo Alto, CA | $3,600 | 1 |
| , MD | Medical Oncology | Dallas, TX | $3,480 | 1 |
| , MD | Medical Oncology | Saint Louis, MO | $3,352 | 1 |
| , MD | Internal Medicine | Nashville, TN | $2,674 | 1 |
| , M.D | Medical Oncology | Fort Myers, FL | $2,188 | 1 |
| , M.D | Internal Medicine | Birmingham, AL | $14.97 | 1 |
| , M.D | Hematology & Oncology | Birmingham, AL | $14.97 | 1 |
| , M.D | Hematology & Oncology | Birmingham, AL | $14.97 | 1 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $9.5M
- Novartis Pharma AG $207,921
- NOVARTIS PHARMACEUTICALS CORPORATION $172,722
Product Information
- Type Drug
- Total Payments $9.9M
- Total Doctors 8
- Transactions 165
About TYKERB
TYKERB is a drug associated with $9.9M in payments to 8 healthcare providers, recorded across 165 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2023. In 2023, $1,500 was paid across 1 transactions to 0 doctors.
The most common payment nature for TYKERB is "Unspecified" ($9.9M, 99.8% of total).
TYKERB is associated with 20 research studies, including "PHASE II TRIAL OF PULSE DOSING OF LAPATINIB IN COMBINATION WITH TEMOZOLOMIDE AND REGIONAL RADIATION THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME" ($3.0M).